Remdesivir Reduces Mortality in Hemato-Oncology Patients with COVID-19.

ABSTRACT:

Introduction

Remdesivir is the first agent with proven clinical efficacy against coronavirus disease 2019 (COVID-19); however, its benefit is associated with early use, and its efficacy has been poorly studied in patients with hemato-oncological diseases, who have an increased risk of a severe course of infection. This study aimed to assess the effects of remdesivir on mortality, mechanical ventilation, and the duration of hospitalization in both the general population and in patients with hemato-oncological diseases.

Materials and methods

Longitudinal data for 4287 patients with confirmed COVID-19 were analyzed, including a subset of 200 individuals with hemato-oncological diseases. In total, 1285 (30.0%) patients received remdesivir, while the remaining patients were treat

SUBMITTER: Aksak-Was BJ 

PROVIDER: S-EPMC9423106 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature